Somaxon Hits Par With IP Suit Over Silenor Generic
Somaxon and patent owner ProCom One Inc. lodged their complaint against parent Par and subsidiary Par Pharmaceutical Inc. in the U.S. District Court for the District of Delaware.
The U.S. Food and Drug Administration approved the prescription sleep aid Silenor, an oral tablet formulation of doxepin, in March.
At issue is U.S. Patent Number 6,211,229, titled "Treatment...
To view the full article, register now.